JCP
STML

Jabre Capital Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Jabre Capital Partners’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$332K – 121
2018
Q3 		$332K Sell
20,000
-863
-4% -$13.8K 0.11% 108
2018
Q2 		$335K Buy
+20,863
New +$372K 0.02% 145

Other funds holding STML

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Jabre Capital Partners's STML Position: Q4 2018 in Review

Jabre Capital Partners sold out of Stemline Therapeutics, Inc. (STML) in Q4 2018, closing a stake of 20,000 shares — an estimated $332K sold.

Jabre Capital Partners first reported a position in STML in Q2 2018 and held it in 2 quarters. The position peaked at $335K in Q2 2018. 92 funds tracked by Wall St. Rank hold STML as of Q4 2018.

  • Jabre Capital Partners reported no remaining Stemline Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 20,000 Stemline Therapeutics, Inc. shares in Q4 2018, an estimated $332K.
  • Jabre Capital Partners first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • Jabre Capital Partners's Stemline Therapeutics, Inc. position peaked at $335K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.